Amundi Has $246.27 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Amundi reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 4.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,321,197 shares of the medical research company’s stock after selling 161,211 shares during the period. Amundi owned about 0.56% of Edwards Lifesciences worth $246,266,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Edwards Lifesciences by 33.5% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 127,436 shares of the medical research company’s stock valued at $10,411,000 after purchasing an additional 31,972 shares during the last quarter. Aviance Capital Partners LLC lifted its position in Edwards Lifesciences by 8.3% during the fourth quarter. Aviance Capital Partners LLC now owns 7,794 shares of the medical research company’s stock worth $577,000 after acquiring an additional 600 shares during the last quarter. Destination Wealth Management lifted its position in Edwards Lifesciences by 12.6% during the fourth quarter. Destination Wealth Management now owns 7,893 shares of the medical research company’s stock worth $584,000 after acquiring an additional 881 shares during the last quarter. Callan Family Office LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $557,000. Finally, E Fund Management Co. Ltd. lifted its position in Edwards Lifesciences by 63.6% during the fourth quarter. E Fund Management Co. Ltd. now owns 5,846 shares of the medical research company’s stock worth $433,000 after acquiring an additional 2,273 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on EW shares. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.36 on Monday. The firm’s fifty day moving average price is $72.26 and its two-hundred day moving average price is $70.39. The stock has a market cap of $41.37 billion, a PE ratio of 10.10, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,150,791.86. The trade was a 27.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This trade represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.